Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711809 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL26046497 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL1711248 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL12275013 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL6097554 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL24267673 | 0.76 | HSD11B1 (0.41) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL10516953 | 0.75 | PDE4B (0.40) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL12955029 | 0.73 | CHRM2 (0.40) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL12954976 | 0.73 | CHRM2 (0.40) | CHRM2CHRM1CHRM3NR1H2HSD11B1 | |
| SCHEMBL25201897 | 0.73 | CHRM2 (0.44) | CHRM2CHRM1CHRM3NR1H2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4652161-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | Uppthera, Inc. (KR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2025-01-23 | — | — | US | disclosed |
| EP-2895488-B1 | TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2024-10-01 | — | — | US | disclosed |
| WO-2024155112-A1 | 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS | UPPTHERA, INC. (KR) | 2024-07-25 | — | — | WO | disclosed |
| EP-4347580-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| WO-2022254362-A1 | 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND MEDICAL USES THEREOF | NOVARTIS AG (CH) | 2022-12-08 | — | — | WO | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | MERCK SHARP & DOHME LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2008112734-A1 | HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS | TARGACEPT, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008075006-A1 | PIPERLDINUM COMPOUNDS FOR TREATMENT OF OBSTRUCTIVE PULMONARY DISEASES ( COPD) | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008008517-A2 | BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
| EP-0900204-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6124312-A | ACTIVE DRUG FOR TREATING ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0900204-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1997040016-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | CHRM2 4722/4885CHRM1 4635/4885CHRM3 4631/4885 |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | CHRM2 213/4885CHRM1 186/4885CHRM3 225/4885 |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | CHRM2 4722/4885CHRM1 4635/4885CHRM3 4631/4885 |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, HBG1, HBG2 | CHRM2 4722/4885CHRM1 4635/4885CHRM3 4631/4885 |
| US-20090239843-A1 | Bridged diazepan orexin receptor antagonists | HCRTR2, HCRTR1, CRHR1 | CHRM2 520/4885CHRM1 437/4885CHRM3 306/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | CHRM2 4673/4885CHRM1 4455/4885CHRM3 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.